Literature DB >> 7587757

Effect of intervention in inflammatory bowel disease on health-related quality of life: a critical review.

R G Maunder1, Z Cohen, R S McLeod, G R Greenberg.   

Abstract

UNLABELLED: Health-related quality of life (HRQOL) is a quantitative measurement of subjective perception of health state, including emotional and social aspects. It can be reliably measured with several valid instruments. Previous reviews of the literature suggested inadequate attention to HRQOL in studies of interventions in inflammatory bowel disease.
PURPOSE: This study was undertaken to assess the current status of the quality of measurement of HRQOL in studies of inflammatory bowel disease and to review the clinical conclusions warranted by the literature.
METHOD: Medicine was searched for articles relating to ulcerative colitis, Crohn's disease, or inflammatory bowel disease and quality of life since 1981. The articles found were reviewed for citations of further articles. The adequacy of HRQOL measure was assessed and graded, and the study design was categorized to assess the strength of the literature on the whole.
RESULTS: A trend was found toward higher quality of HRQOL measurement in the period 1988 to 1994 compared with 1981 to 1987. Most of the improvement was because of increased use of standardized and multidomain but unvalidated and unpublished questionnaires for measurement.
CONCLUSIONS: Confidence in the following clinical conclusions in studies of surgical interventions in inflammatory bowel disease is limited by study design: that pelvic pouch is not inferior to ileostomy, that specific domains of HRQOL are differentially affected by different surgical procedures, and (with less confidence) that surgery is helpful in Crohn's disease. Medical studies have demonstrated that high quality HRQOL measures can be integrated into randomized, prospective trials. Clinically equivalent treatments have shown differential effects or HRQOL: 9 mg daily of budesonide is superior to 15 mg, and hydrocortisone foam enemas are superior to prednisolone. Home parenteral nutrition has received modest support, limited again by study design. It is recommended that standard tests of HRQOL be used to increase comparability of studies and to increase the quality of this literature in general. In particular the Inflammatory Bowel Disease Questionnaire, Rating Form of Inflammatory Bowel Disease Concerns, and Direct Questioning of Objectives are recommended.

Entities:  

Mesh:

Year:  1995        PMID: 7587757     DOI: 10.1007/BF02048330

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

Review 1.  Health related quality of life in inflammatory bowel disease: the impact of surgical therapy.

Authors:  Konstantin Umanskiy; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

Review 2.  Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures.

Authors:  Nicholas J Talley; Ingela Wiklund
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

3.  Does better disease-related education improve quality of life? A survey of IBD patients.

Authors:  S Verma; H H Tsai; M H Giaffer
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

4.  Self-care agency and quality of life among adults diagnosed with inflammatory bowel disease.

Authors:  D M Smolen; R Topp
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

5.  Further Validation of the Crohn's and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy.

Authors:  Laith Alrubaiy; Rafid Sikafi; Hayley Anne Hutchings; Ian Arnott; John Gordon Williams
Journal:  Clin Pract       Date:  2022-06-10

Review 6.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.